NovoCure (NASDAQ:NVCR) Shares Gap Down – What’s Next?

NovoCure Limited (NASDAQ:NVCR) gapped down prior to trading on Thursday. The stock had previously closed at $14.17, but opened at $12.61. NovoCure shares last traded at $12.8290, with a volume of 886,653 shares changing hands.

More NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. Its adjusted loss of $0.09 per share was substantially narrower than the expected $0.23 loss and the year-ago loss of $0.33. NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat
• Positive Sentiment: Management raised its 2026 guidance, reinforcing expectations for continued revenue growth and improved financial performance. The earnings call also provided additional detail on the company’s commercial and clinical strategy. NovoCure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
• Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 for pancreatic cancer. The partnership could expand the company’s pipeline and future indications. NovoCure and Verastem Collaboration
• Neutral Sentiment: Despite the earnings beat, NovoCure remains unprofitable, with a negative net margin and return on equity. Investors therefore remain focused on whether higher revenue and raised guidance can translate into sustainable profitability. NovoCure Third-Quarter Results
• Negative Sentiment: NovoCure’s CEO said adoption of the Optune Pax system was slowed by competition from Revolution Medicines’ daraxonrasib. Wedbush characterized the issue as a disruption rather than direct competition, but the slower adoption raises concerns about near-term commercial momentum. Optune Pax Adoption Commentary
• Negative Sentiment: Wells Fargo lowered its price target for NVCR from $20 to $15 and maintained an “equal weight” rating. Although the new target implies upside, the sharp reduction signals reduced confidence in the stock’s near-term risk-reward profile. Wells Fargo NovoCure Rating

Analyst Ratings Changes

A number of equities analysts have recently weighed in on NVCR shares. Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a research report on Friday, July 24th. JPMorgan Chase & Co. started coverage on shares of NovoCure in a research note on Monday, July 13th. They issued a “neutral” rating and a $17.00 target price for the company. Wedbush boosted their price target on NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Wells Fargo & Company reduced their price target on NovoCure from $20.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, Wall Street Zen raised NovoCure from a “hold” rating to a “buy” rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NovoCure currently has an average rating of “Hold” and a consensus price target of $20.80.

NovoCure Trading Up 0.3%

The business’s 50-day moving average is $15.79 and its two-hundred day moving average is $14.79. The company has a current ratio of 2.89, a quick ratio of 2.70 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.53 billion, a PE ratio of -12.41 and a beta of 0.99.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.14. The business had revenue of $193.40 million for the quarter, compared to the consensus estimate of $182.28 million. NovoCure had a negative return on equity of 36.18% and a negative net margin of 16.78%. The company’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the business posted ($0.33) EPS. On average, analysts predict that NovoCure Limited will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On NovoCure

Several institutional investors and hedge funds have recently made changes to their positions in the business. Elevation Wealth Partners LLC raised its holdings in shares of NovoCure by 196.4% during the third quarter. Elevation Wealth Partners LLC now owns 1,731 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 1,147 shares during the last quarter. Strs Ohio raised its stake in NovoCure by 2.2% during the 1st quarter. Strs Ohio now owns 59,400 shares of the medical equipment provider’s stock valued at $647,000 after acquiring an additional 1,300 shares in the last quarter. Allworth Financial LP boosted its position in NovoCure by 182.0% during the 2nd quarter. Allworth Financial LP now owns 2,721 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 1,756 shares during the period. Kera Capital Partners Inc. lifted its holdings in NovoCure by 9.0% in the first quarter. Kera Capital Partners Inc. now owns 21,454 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 1,763 shares during the period. Finally, First Bancorp Inc ME bought a new position in shares of NovoCure in the second quarter valued at approximately $38,000. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Company Profile

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.